NCT00311740

A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

A Multi-center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40 & 80 mg) and Hydrochlorothiazide (6.25 & 12.5 mg) Combined & Alone in Essential Hypertensive Patients] - Double-blind Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 582 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: —

Summary

The purpose of this study is to compare the effect of the fixed combination of valsartan+hydrochlorothiazide (HCTZ) on blood pressure reduction with valsartan and HCTZ alone and whether the combination treatments are safe and well tolerated. The study aims to establish a dose response relationship for both monotherapies and the combinations. This study is being conducted in Japan.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Valsartan
DRUG	Hydrochlorothiazide

Timeline

• Start date: 2006-03-01
• Primary completion: 2006-09-01
• Completion: 2006-09-01
• First posted: 2006-04-06
• Last updated: 2017-02-23

Locations

1 site across 1 country: Japan